A Q&A with CEO Jamie Hodgson

We recently sat down with Jamie Hodgson, CEO of Glen Clova, for a fireside chat to ask the questions investors want answered. Jamie set out Glen Clova’s ambition to transform the treatment of chronic inflammatory diseases such as severe eczema and asthma, using a platform designed to move beyond frequently dosed monoclonal antibodies. Instead, the company aims to stimulate the body to produce its own antibodies, with the potential for dosing just once or twice a year.

Jamie also highlighted Glen Clova’s differentiation through its scalable, one‑step manufacturing approach and strong intellectual property position, alongside a parallel veterinary medicine opportunity in canine atopic dermatitis that could deliver near‑term, non‑dilutive capital. Looking ahead, the focus is on demonstrating safety and scalability, with a potential strategic exit opportunity in the 2028–2029 timeframe.

Q: So the obvious question is, when is Glen Clova likely to exit?

“We have got the next two to three years where we’re really going to try and prove that what we’ve got here is scalable beyond what we’ve done so far, and that we can surpass any regulatory safety hurdles that we need from a preclinical development perspective. 

The ideal scenario would be based on the valuations outlined in our investment packs. By the end of 2029, we would expect to be at a point where a large pharmaceutical company could be interested, not only in the lead asset ahead of first‑in‑human trials, but also in the broader business. Given current industry dynamics, large pharma pipelines are increasingly looking to diversify, and we believe this could drive interest in both the company as a whole and the underlying technology we have developed.”

We hope you enjoy the full Q&A – simply click the video preview below to watch.